Skip to main content
ZheJiang Tailin Bioengineering Co.,Ltd logo

ZheJiang Tailin Bioengineering Co.,Ltd — Investor Relations & Filings

Ticker · 300813 ISIN · CNE100003S89 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,000 across all filing types
Latest filing 2026-06-03 Capital/Financing Update
Country CN China
Listing Shenzhen Stock Exchange 300813

About ZheJiang Tailin Bioengineering Co.,Ltd

https://www.tailingood.com

ZheJiang Tailin Bioengineering Co.,Ltd. specializes in the research, development, and manufacturing of high-tech equipment for life sciences and pharmaceutical engineering. The company provides integrated solutions for microbial control, sterility testing, and aseptic processing. Its core product portfolio includes sterility test canisters and pumps, microbial limit testing systems, and hydrogen peroxide vapor (VHP) decontamination units. Tailin also develops advanced isolator technology for containment and aseptic applications, alongside analytical instruments such as Total Organic Carbon (TOC) analyzers and filter integrity testers. These products are designed to meet international regulatory standards, including GMP, USP, and EP. The company serves sectors such as biopharmaceuticals, medical devices, and laboratory research, focusing on product safety and quality through specialized engineering and microbial detection technologies.

Recent filings

Filing Released Lang Actions
关于申请向不特定对象发行可转换公司债券审核问询函回复及申请文件更新的提示性公告
Capital/Financing Update Classification · 88% confidence The document is a Chinese stock exchange announcement regarding the company’s application to issue convertible corporate bonds to unspecified investors, the receipt of an exchange inquiry letter, and the company’s reply and updated application files. This pertains directly to a capital raising and financing activity. Therefore, it is classified as a Capital/Financing Update (CAP).
2026-06-03 Chinese
关于浙江泰林生物技术股份有限公司向不特定对象发行可转换公司债券审核问询函中有关财务事项的说明
Capital/Financing Update Classification · 87% confidence The document is a detailed response (“说明”) to a review inquiry letter (“审核问询函”) from the Shenzhen Stock Exchange concerning the company’s proposed issuance of convertible corporate bonds to unspecified investors. It provides extensive financial disclosures and explanations tied directly to the company’s financing activity. This is not a periodic earnings release or annual/interim report but relates specifically to the financing process. Accordingly, it should be classified under Capital/Financing Update (CAP).
2026-06-03 Chinese
长城证券股份有限公司关于浙江泰林生物技术股份有限公司向不特定对象发行可转换公司债券之上市保荐书
Capital/Financing Update Classification · 83% confidence The document is a detailed listing sponsor’s submission (“上市保荐书”) for Zhejiang Tailin Bioengineering Co., Ltd.’s convertible bond issuance, prepared by the underwriting sponsor (Great Wall Securities). It contains full offering details, bond terms, issuer background, financial statements, risks, and underwriting commitments -- all elements of a primary fundraising transaction. This is not merely an announcement of report release nor an annual or interim report, but the actual issuance prospectus-style document for a financing event. Therefore it falls under Capital/Financing Update (CAP).
2026-06-03 Chinese
长城证券股份有限公司关于浙江泰林生物技术股份有限公司向不特定对象发行可转换公司债券之发行保荐书
Capital/Financing Update Classification · 91% confidence The document is a detailed underwriting sponsor’s letter (“发行保荐书”) by Great Wall Securities for Zhejiang Tailin Bioengineering’s issuance of convertible corporate bonds. It outlines the bond issuance conditions, legal compliance, internal review, bond terms (coupon, maturity, conversion mechanics), and sponsors’ opinions—clearly a capital raising/financing activity. This falls under Financing Update (CAP).
2026-06-03 Chinese
国浩律师（杭州）事务所关于浙江泰林生物技术股份有限公司向不特定对象发行可转换公司债券之补充法律意见书（一）
Regulatory Filings Classification · 85% confidence The document is a “Supplementary Legal Opinion” provided by the company’s legal counsel concerning the issuance of convertible bonds and responses to an exchange inquiry. It is not an annual or interim financial report, earnings release, share issuance announcement, M&A filing, proxy, or any other specialized category. It is a compliance/legal opinion document tied to a securities issuance. Under the scheme given, such miscellaneous regulatory/legal compliance filings fall into the “Regulatory Filings” category (RNS).
2026-06-03 Chinese
浙江泰林生物技术股份有限公司向不特定对象发行可转换公司债券募集说明书（修订稿）
Capital/Financing Update Classification · 95% confidence The document is the full prospectus (“募集说明书（修订稿）”) for Zhejiang Tailin Bioengineering’s convertible bond issuance to unspecified investors. It details the terms of the debt offering, use of proceeds, risk factors, financial information, and issuance scale. This is a substantive financing/fundraising document rather than a mere announcement or regulatory attestation. It best fits “Capital/Financing Update” (CAP).
2026-06-03 Chinese

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.